Accu Dava Inc Personalized Molecular Cancer Diagnostics Saving

Accu. Dava, Inc. Personalized Molecular Cancer Diagnostics Saving lives, Reducing costs

What problems do we solve? According to WHO, 14 million cancer patients are treated annually with conventional chemotherapy. Problem Nearly 50% of these chemotherapy patients do not get much benefit from the treatments. They experience all the anguishes of chemotherapy but their tumors progress and their condition persists. Physicians then have to switch to a different regimen of chemotherapy, if it is not too late! Accu. Dava, Inc. Personalized Molecular Cancer Diagnostics

Accu. Dava solution We have developed an unprecedented molecular process to improve efficacy of personalizing cancer chemotherapy. Our test enables physicians to avoid ineffective drugs and select suitable treatments, based on a patient’s tumor molecular characteristics – before treatment begins. All this from a 60 -minute test on a tumor sample. Accu. Dava, Inc. Personalized Molecular Cancer Diagnostics

Accu. Dava’s technology is based on the identification of two “Cell-Surface Glycan Biomarkers” Specificity of Accu. Dava Biomarkers §It is on the cell-surface not within the cell. §It is a carbohydrate motif, not genomic or protein. - Glycans are dynamic molecules involved in cell-signaling, and on the front line of cell communication and defense. Accu. Dava, Inc. Personalized Molecular Cancer Diagnostics

Presentation of the cell-surface glycan biomarker overexpression on cancer cells Glycan biomarker Nucleus Chemo-sensitive cancer cell (10 X more biomarker on chemo-susceptible than chemo-resistant) Accu. Dava, Inc. Personalized Molecular Cancer Diagnostics Nucleus Chemo-Resistant cancer cell

Detecting Method of the glycan biomarker Biopsy or Surgery Tissue section on slide tumor Two steps staining Accu. Dava, Inc. Personalized Molecular Cancer Diagnostics

Histochemical staining of retrospective human ovarian cancer tumor sections Accu. Dava, Inc. Personalized Molecular Cancer Diagnostics

Why Accu. Dava Technology? § Our products will be offered as “Prognostic Kits” for personalized cancer chemotherapy § Directly test the cancer specimen § Perform on-site in regular clinical lab setting § Kit components are readily available Accu. Dava, Inc. Personalized Molecular Cancer Diagnostics

Product/Service Concept: § Two “Companion Diagnostic Kits” will be introduced under the trade name SETAXTM and SEPEXTM for predicting platinum-drugs response in ovarian cancer chemotherapy. § SETAXTM and SEPEXTM provide exclusive molecular information for chemotherapy management, by identifying patients who gain benefit from standard therapy with platinum drugs. § These tests can also be offered as a laboratory service, during the FDA clearance process for marketing SETAXTM and SEPEXTM. Accu. Dava, Inc. Personalized Molecular Cancer Diagnostics

Science team Nahid Razi, Ph. D. , Founder and Principle Investigator Afshin Bahador, M. D. , Director of Clinical Research OBGYN and Surgical oncologist South Coast Gynecologic Oncology, Inc. Nissi Varki, M. D. , Professor of Pathology at UCSD, Director of the UCSD histology and pathology laboratory Nathalie Scholler, M. D. , Ph. D. , Professor of OBGYN and Oncology at University of Pennsylvania, Specialist in ovarian cancer biomarkers- Meso. Mark. TM Accu. Dava, Inc. Personalized Molecular Cancer Diagnostics

Management Team Nahid Razi - President Hedi Jafari, MBA - CFO Financial manager at UCSD Afshin Bahador, MD - Managing partner David Larson - Business advisor CFO/COO True Diagnostics Scientific Advisor Professor Ulf Lindahl- Senior member of the Swedish Royal Academy of Science, member of the Nobel Prize committee Accu. Dava, Inc. Personalized Molecular Cancer Diagnostics

Achievements § 10 years of investigations identified two “glycan biomarkers” for drug response §Developed assays for detecting those biomarkers §Verified the assays' reliability, reproducibility and specificity on human cancer specimens §Validated the clinical correlation of the biomarkers with drug efficacy, on retrospective ovarian cancer tumor sections §Applied for 2 patents, received 1, the other in process Accu. Dava, Inc. Personalized Molecular Cancer Diagnostics

Intellectual Property Two Patents filed by Knobbe-Martens §One issued patent (2009) §One pending (recently filed) §Filed under the name of Nahid Razi, Ph. D. Accu. Dava, Inc. Personalized Molecular Cancer Diagnostics

2 milestones to Market Milestone #1 - Preclinical Verification § 100 -200 ovarian cancer patients (sites identified) § 12 -18 months §Create protocols for Clinical trial Milestone #2 - Clinical Studies + PMA (FDA Clearance) §FDA required number of ovarian cancer patients § 18 -24 months (est. ) §Produce data to support PMA for FDA approval Accu. Dava, Inc. Personalized Molecular Cancer Diagnostics